Cardiovascular Journal of Africa: Vol 25 No 5 (September/October 2014)

43 / 74

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 25, No 5, September/October 2014 AFRICA 237
ventricular hypertrophy in hypertension: the MAVI study. Ital Heart J
2000; 3: 207–215.
5. Buckley MG, Markandu ND, Miller MA, Sagnella GA, MacGregor
AM. Plasma concentrations and comparisons of brain and atrial natriu-
retic peptide in normal subjects and in patients with essential hyperten-
sion. J Hum Hypertens 1993; 7: 245–250.
6. Weber T, Auer J, Eber B. The diagnosis and prognostic value of brain
natruiretic peptide and aminoterminal (NT)-pro brain natriuretic
peptide. Curr Pharm Des 2005; 4: 511–525.
7. Bolger AP, Sharma R, Li W, Leenarts M, Kalra PR, Kemp M, et al.
Neurohormonal activation and the chronic heart failure syndrome in
adults with congenital heart disease. Circulation 2002; 106: 92–99.
8. Garcia S, Akbar MS, Ali SS, Kamdar F, Tsai MY, Duprez DA.
N-terminal pro B-type natriuretic peptide predicts mortality in patients
with left ventricular hypertrophy. Int J Cardiol 2010; 143: 349–352.
9. Talwar S, Siebenhofer A, Williams B, Ng L. Influence of hypertension,
left ventricular hypertrophy and left ventricular systolic dysfunction on
plasma N terminal pro BNP. Heart 2000; 83: 278–282.
10. Stewart S, Libhaber E, Carrington M, Damasceno A, Abbasi H, Hansen
C, et al. The clinical consequences and challenges of hypertension in
urban-dwelling black Africans: insights from the Heart of Soweto study.
Int J Cardiol 2011; 146(1): 22–27.
11. Ojji D, Stewart S, Ajayi S, Mamven M, Sliwa K. A predominance of
hypertensive heart failure in the Abuja Heart Study cohort of urban
Nigerians: a prospective clinical registry of 1515 de novo cases. Eur J
Heart Fail 2013; 8: 835–842.
12. Damasceno A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojji D, et
al. The causes, treatment and outcome of acute heart failure in 1006
Africans from 9 countries. Arch Intern Med 2012; 172: 1386–1394.
13. Tumuklu MM, Erkormaz U, Ocal A. The impact of hypertension and
hypertension-related left ventricle hypertrophy on right ventricle func-
tion. Echocardiography 2007; 4: 374–384.
14. Schillaci G, Pasqualini L, Verdecchia P, Vaudo G, Marchesi S, Porcellati
C, et al. Prognostic significance of left ventricular diastolic dysfunction
in essential hypertension. J Am Coll Cardiol 2002; 39: 2002–2011.
15. The Seventh Report of the Joint National Committee on Prevention,
Evaluation and Treatment of High Blood Pressure. US Department
of Health and Human Services. NIH Publication August 2004; No
04-5230.
16. The Task Force for the Diagnosis and Treatment of Chronic Heart
Failure of the European Society of Cardiology: guidelines for the treat-
ment and diagnosis of chronic heart failure: an executive summary
(update 2005). Eur Heart J 2005; 26: 1115–1140.
17. Criteria Committee, New York Heart Association. Diseases of heart
and blood vessels. Nomenclature and Criteria for Diagnosis, 6th edn.
Boston: Little, Brown, 1964: 114.
18. Prickett TC, Yandle TG, Nicholls MG, Espiner EA, Richards AM.
Identification of amino-terminal pro-C-type natriuretic peptide in
human plasma. Biochem Biophys Res Commun 2001; 286: 513–517.
19. Sahn DJ, De Maria A, Kisslo J,Weyman A. Recommendations regard-
ing quantitation in M-mode echocardiography: results of a survey of
echocardiographic measurements. Circulation 1978; 58: 1072–1083.
20. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echo-
cardiographic volume determinants: echocardiographic-angiographic
correlations in the presence of absence of asynergy. Am J Cardiol 1976;
37: 7–11.
21. Park SH, Shub C, Nobrega TP, Bailey KR, Seward JB. Two-dimensional
echocardiographic calculations of left ventricular mass as recommended
by the American Society of Echocardiography: correlation with autopsy
and M-mode echocardiography. J Am Soc Echocardiogr 1996; 2:
119–128.
22. Palmieri V, Dahlof B, De Quattro V,Sharpe N, Bella JN, de Simon G.
Reliability of echocardiographic assessment of left ventricular structure
and function: the PRESERVE study. Prospective randomized study
evaluating regression of ventricular enlargement. J Am Coll Cardiol
1999: 34: 1625–1632.
23. Jurcut R, Giusca S, La Gerche A, Vasile S, Ginghina C, Voigt JU. The
echocardiographic assessment of the right ventricle: what to do in 2010?
Eur J Echocardiogr 2010; 11: 81–96.
24. Irzmanski R, Banach M, Piechota M, Kowalski J, Barylski M,
Ciemiewski C, et al. Atrial and brain natriuretic peptide and endothe-
lin-1 concentration in patients with idiopathic arterial hypertension: the
dependence on the selected morphological parameters. Clin Hypertens
2007; 3: 149–164.
25. Sagnella GA. Measurements and significance of circulating natriuretic
peptides in cardiovascular disease. Clin Sci (London) 1998; 5: 519–529.
26. Pemberton CJ, Johnson ML, Yandle TG, Espiner EA. Deconvolution
analysis of cardiac natriuretic peptides during acute volume overload.
Hypertension 2000; 36: 355–359.
27. Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW, et
al. Impact of age and sex on plasma natriuretic peptide levels in healthy
adults. Am J Cardiol 2002; 90: 254–258.
28. Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R, et
al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur
Heart J 2003; 24: 1710–1718.
29. Fruhwald FM, Fahrleitner A, Watzinger N, Fruhwald S, Dobnig H,
Shumacher M, et al. Natriuretic peptides in patients with diastolic
dysfunction due to idiopathic dilated cardiomyopathy. Eur Heart J 1999;
20: 1415–1423.
30. Yu CM, Sanderson JE, Shum IO, Chan S, Yeung LY, Hung YT, et al.
Diastolic dysfunction and natriuretic peptides in systolic heart failure.
Higher ANP and BNP levels are associated with the restrictive filling
pattern. Eur Heart J 1996; 17: 1694–1702.
31. Troughton RW, Prior DL, Pereira JJ, Martin M, Fogarty A, Morehead
A, et al. Plasma B-type natriuretic peptide levels in systolic heart failure:
importance of left ventricular diastolic function and right ventricular
systolic function. J Am Coll Cardiol 2004; 43: 416–422.
32. Reesink HJ, Tulevski II, Marcus JT, Boomsma F, Kloek JJ, Vonk, et al .
Brain natriuretic peptide as noninvasive marker of the severity of right
ventricular dysfunction in chronic thrombembolic pulmonary hyperten-
sion. Am Thorac Surg 2007; 84: 537–543.
33. Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natruiretic peptide
levels in proportion to the extent of right ventricular dysfunction in
pulmonary hypertension. J Am Coll Cardiol 1998; 31: 202–208.
34. Nagaya N, Nishikimi T, Uematsu M,Satoh T, Kyotani S, Sakami F, et
al. Plasma brain natriuretic peptide as a prognostic indicator in patients
with primary pulmonary hypertension. Circulation 2000; 102: 865–870.
35. Vakili B, Okin P, Devereux RB. Prognostic implications of left ventricu-
lar hypertrophy. Am Heart J 2001; l41: 334–341.
36. Goldberg RJ, Ciampa J, Lessard D, Meyer TE, Spencer FA. Long-term
survival after heart failure: a contemporary population-based perspec-
tive. Arch Intern Med 2007; 167: 490–496.
37. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in
subjects with normal versus reduced left ventricular ejection fraction:
prevalence and mortality in a population-based cohort. J Am Coll
Cardiol 1999; 33: 1948–1955.
38. Mocumbi AO, Sliwa K. Women’s cardiovascular heath in Africa. Heart
2012; 98: 450–455.
39. Paget V, Legedz L, Gaudebout N, Bricca G, Milon H, Vincent M,
Lantelme P. N-terminal pro-brain natriuretic peptide: a powerful predic-